The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

The biotech sector is transitioning away from a framework dominated by long-term research spending toward one in which scientific progress can be directly reflected in financial valuation. As drug ...

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...

RHHBY's Gazyva gets FDA review for lupus as strong trial data and pipeline wins across neurology and MS bolster growth outlook.

Biogen BIIB announced that it has entered into a definitive agreement with TJ Biopharma, under which it will acquire TJ Bio’s ...

Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...

Systemic lupus erythematosus (SLE) involves ongoing inflammation, tissue damage from immune complexes, and incomplete immune resolution. A key factor ...

Sixth paragraph, fifth sentence of release issued April 20, 2026 at 10 p.m. PT/April 21, 2026 at 1 a.m. ET, should read: In addition, treatment with Gazyva plus standard therapy, versus placebo plus ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...

Transaction will add pro-forma profitable revenue, enhance predictability of financial performance, expand market share, and accelerate the ...

Accurate measurement of HMGB-1, neopterin and sIL-2R supports reliable assessment of immune activation across clinical and ...